The Buckle, Inc. (BKE)

Verve Therapeutics Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Verve Therapeutics stock has a target of 41, which predicts a -22.20% decrease from the current stock price of 52.7.

Price Target: $41.00 (-22.20%)

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	$41	$41	$41	$41
Change	-22.20%	-22.20%	-22.20%	-22.20%

* Price targets were last updated on Mar 18, 2025.

Analyst Ratings

According to 1 stock analyst, the rating for Verve Therapeutics is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	0	0	0	0	0	0
Buy	0	0	0	0	0	0
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	1	1	1	1	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Mauricio Serna UBS	UBS	Hold Maintains $43 → $41	Hold	Maintains	$43 → $41	-22.20%	Mar 18, 2025
Mauricio Serna UBS	UBS	Strong Sell → Hold Upgrades $31 → $46	Strong Sell → Hold	Upgrades	$31 → $46	-12.71%	Nov 12, 2024
Mauricio Serna UBS	UBS	Strong Sell Maintains $32 → $31	Strong Sell	Maintains	$32 → $31	-41.18%	Aug 26, 2024
Mauricio Serna UBS	UBS	Strong Sell Maintains $34 → $32	Strong Sell	Maintains	$34 → $32	-39.28%	May 15, 2024
Mauricio Serna UBS	UBS	Hold → Strong Sell Downgrades $37 → $34	Hold → Strong Sell	Downgrades	$37 → $34	-35.48%	Jan 5, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

1.25B

Increased by 2.24%

from 1.22B

Revenue Next Year

1.27B

Increased by 2.17%

from 1.25B

EPS This Year

3.73

Decreased by -4.06%

from 3.89

EPS Next Year

3.79

Increased by 1.49%

from 3.73

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027	FY 2028
Period Ending	Jan 30, 2021	Jan 29, 2022	Jan 28, 2023	Feb 3, 2024	Feb 1, 2025	Feb 1, 2026	Feb 1, 2027	Feb 1, 2028
Revenue	901.28M	1.29B	1.35B	1.26B	1.22B	1.25B	1.27B	1.32B
Revenue Growth	0.11%	43.64%	3.91%	-6.25%	-3.44%	2.24%	2.17%	3.85%
EPS	2.66	5.16	5.13	4.40	3.89	3.73	3.79	4.04
EPS Growth	24.30%	93.99%	-0.58%	-14.23%	-11.59%	-4.06%	1.49%	6.67%
Forward PE	-	-	-	-	-	14.12	13.91	13.04
No. Analysts	-	-	-	-	-	3	2	2

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028
High	1.3B	1.3B	1.4B
Avg	1.2B	1.3B	1.3B
Low	1.2B	1.2B	1.3B

Revenue Growth

Revenue Growth	2026	2027	2028
High	7.2%	6.2%	7.9%
Avg	2.2%	2.2%	3.9%
Low	-1.5%	-0.9%	0.8%

EPS Forecast

EPS	2026	2027	2028
High	3.94	3.94	4.20
Avg	3.73	3.79	4.04
Low	3.57	3.68	3.92

EPS Growth

EPS Growth	2026	2027	2028
High	1.2%	5.5%	10.9%
Avg	-4.1%	1.5%	6.7%
Low	-8.3%	-1.5%	3.5%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.